Cytara IV Infusion

Cytarabine

500 mg/vial

Healthcare Pharmaceuticals Ltd.

Pack size	500 mg
Unite Price	950.00 BDT

Indications

Cytara IV Infusion is used for: Acute myeloid leukaemia, acute lymphocytic leukaemia (ALL), lymphomas, Leukaemic meningitis

Adult Dose

Acute Nonlymphocytic Leukemia IV administration for remission induction 100-200 mg/sq.meter/day for 5-10 days; begin second course in 2-4 weeks after initial therapy if necessary OR 100 mg/sq.meter for 7 days OR 100 mg/sq.meter/dose q12hr for 7 days Intrathecal (IT) administration for remission induction 5-75 mg/sq.meter q2-7Days until CNS findings normalize IV administration for remission maintenance 70-200 mg/sq.meter/day for 2-5 days at monthly intervals IM administration for remission maintenance 1-1.5 mg/kg single dose for maintenance at 1- 4 week intervals Meningeal Leukemia IT administration 30 mg/sq.meter intrathecal (IT) q4Days until CSF findings normal plus one additional dose Refractory Leukemia IV administration 3 g/sq.meter IV (infusion over 1-3 hours) q12hr x 4-12 doses Repeat q2-3Weeks

Child Dose

Renal Dose

Administration

IV Administration Rapid IV, infusion over 1-3 hr, or SC intrathecal Has been administered by IM & continuous SC infusion IT: Patient should lie flat for 1 hour after lumbar puncture Liposomal: To reduce incidence of arachnoiditis, administer dexamethasone concurrently IV Preparation Reconstitute vials in BWI containing benzyl alcohol 0.945% as follows (CAUTION: Do not use benzyl alcohol for intrathecal inj) 100 mg vial: add 5 mL diluent to 20 mg/mL 500 mg vial: add 10 mL diluent to 50 mg/mL 1 g vial: add 10 mL diluent to 100 mg/mL 2 g vial: add 20 mL diluent to 100 mg/mL

Contra Indications

Hypersensitivity; pregnancy and lactation.

Precautions

Hepatic and renal dysfunction, severe infections, preexisting drug-induced bone marrow suppression. Monitor WBC, platelet counts and blood uric acid frequently. Assess renal and hepatic function periodically. Lactation: not known if excreted in breast milk, avoid

Pregnancy-Lactation

Pregnancy Category: D Lactation: not known if excreted in breast milk, avoid

Interactions

May reduce efficacy of gentamicin, digoxin and flucytosine. Potentially Fatal: Potentiates bone marrow depression with radiotherapy and other myelotoxic drugs.

Side Effects

Side effects of Cytarabine : 1-10% Anorexia, Nausea, Vomiting, Diarrhea, Oral/anal inflammation, Thrombophlebitis, Bleeding, Myelosuppression, Rash, Fever, Hepatic dysfunction Frequency Not Defined Headache, Neuropathy, Chest pain, Pericarditis, Pneumonia, Anemia, Bleeding, Leukopenia, Thrombocytopenia, Kidney disease, Infectious disease, Sepsis, "Cytarabine syndrome": fever, myalgia, bone pain, rash, conjunctivitis, malaise, Skin ulcers, Cellulitis, Urinary retention, Neuritis, Jaundice, Anaphylaxis Potentially Fatal: Convulsions. Cerebellar dysfunction, respiratory distress syndrome, GI perforation, bone marrow suppression.

Mode of Action

Cytarabine acts by interfering with DNA synthesis specifically at the S-phase of the cell cycle. It is a potent myelosuppressant and requires careful haematological monitoring during its use. It also has antiviral property.

Note

Cytara 500 mg/vial IV Infusion generic name is Cytarabine. Cytara 500 mg/vial IV Infusion is manufactured by Healthcare Pharmaceuticals Ltd.Cytara is availble in all over Bangladesh. Mes BD drug index information on Cytara IV Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Cytarabine :

Injection

Cytarabine 5ml ^100mg/5ml

Choongwae Pharma Corporation,Korea

Injection

Cytabin ^{100 mg/vial}

Beacon Pharmaceuticals Ltd.

Injection

Cytabin ^{500 mg/vial}

Beacon Pharmaceuticals Ltd.

IV Injection

Cytosor ^100mg/ml

Eskayef Pharmaceuticals Ltd.

IV Injection

Cytosor ^500mg/5ml

Eskayef Pharmaceuticals Ltd.